Back to Search
Start Over
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B
- Source :
- Thrombosis and Haemostasis. 117:508-518
- Publication Year :
- 2017
- Publisher :
- Georg Thieme Verlag KG, 2017.
-
Abstract
- SummaryThe safety, efficacy, and prolonged half-life of recombinant factor IX Fc fusion protein (rFIXFc) were demonstrated in the Phase 3 B-LONG (adults/adolescents ≥12 years) and Kids B-LONG (children Supplementary Material to this article is available online at www.thrombosis-online.com.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Time Factors
Adolescent
Recombinant Fusion Proteins
Hemorrhage
030204 cardiovascular system & hematology
Haemophilia
Hemophilia B
Drug Administration Schedule
Factor IX
Young Adult
03 medical and health sciences
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Humans
Haemophilia B
Child
Hemostasis
Coagulants
business.industry
Hematology
Middle Aged
medicine.disease
Antibodies, Neutralizing
Immunoglobulin Fc Fragments
Fc fusion
Treatment Outcome
030220 oncology & carcinogenesis
Immunology
Long term safety
business
Recombinant factor IX
medicine.drug
Subjects
Details
- ISSN :
- 2567689X and 03406245
- Volume :
- 117
- Database :
- OpenAIRE
- Journal :
- Thrombosis and Haemostasis
- Accession number :
- edsair.doi.dedup.....0c10b67eef88edca7ecd10233367cd81
- Full Text :
- https://doi.org/10.1160/th16-05-0398